The allergy vaccines group published its one-year follow-up study of patients using Acarovac Plus, its flagship dust mite allergy vaccine.
A statistically significant reduction in symptom scores was observed at both follow-up visits (four weeks and one year), with a reduction of up to 50% in symptom scores recorded after one year.
Significant improvements in immunological markers were noted at the follow-up visits, said the group.
With over 20% of Europeans allergic to dust mites, sales of house dust mite immunotherapy are expected to increase rapidly over the coming years.
“Acarovac Plus bolsters our portfolio of allergy immunotherapy products on the market in Europe and we look forward to continued good growth,” said chief executive Manuel Llobet.